Skip to main content
Premium Trial:

Request an Annual Quote

This Week in Lancet Oncology: Aug 5, 2011


In Lancet Oncology this week, researchers in China present findings from a phase III study of erlotinib versus chemotherapy as a first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer. The researchers randomly assigned 83 patients to receive erlotinib and 82 to receive gemcitabine plus carboplatin, and found that median progression-free survival was significantly longer in the erlotinib group — 13.1 months — than in the chemotherapy group — 4.6 months. In addition, chemotherapy was associated with more severe side effects than erlotinib. "Compared with standard chemotherapy, erlotinib conferred a significant progression-free survival benefit in patients with advanced EGFR mutation-positive non-small-cell lung cancer and was associated with more favorable tolerability," the authors write. "These findings suggest that erlotinib is important for first-line treatment of patients with advanced EGFR mutation-positive non-small-cell lung cancer."

Also in Lancet Oncology this week, researchers in Spain and the UK present insights from a meta-analysis of studies done on the associations between height and cancer risk in women. Epidemiological studies have shown that taller people are at increased risk for cancer, but the reasons for the association is unclear, the researchers write. The team included data from nearly 1.3 million women who were followed up for a median of 9.4 years. During this time, the team says, 97,376 cancers occurred. "Risk increased for 15 of the 17 cancer sites we assessed, and was statistically significant for ten sites: colon, rectum, malignant melanoma, breast, endometrium, ovary, kidney, CNS, non-Hodgkin lymphoma, and leukemia," the authors write. "Cancer incidence increases with increasing adult height for most cancer sites. The relation between height and total cancer relative risk is similar in different populations."

And finally in Lancet Oncology this week, researchers in the UK examine the effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma. The team randomly assigned 981 patients to the zoledronic acid group and 979 to the clodronic acid group, and found that at a median follow-up of 3.7 years, patients in the zoledronic acid group had a lowed incidence of skeletal-related events than patients in the clodronic acid group. "The results of this study support the early use of zoledronic acid rather than clodronic acid in patients with newly diagnosed multiple myeloma for the prevention of skeletal-related events, irrespective of bone disease status at baseline," the team writes.

The Scan

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.

Study Reviews Family, Provider Responses to Rapid Whole-Genome Sequencing Follow-up

Investigators identified in the European Journal of Human Genetics variable follow-up practices after rapid whole-genome sequencing.

BMI-Related Variants Show Age-Related Stability in UK Biobank Participants

Researchers followed body mass index variant stability with genomic structural equation modeling and genome-wide association studies of 40- to 72-year olds in PLOS Genetics.

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.